Formulation and In Vitro, In Vivo Evaluation of Effervescent Floating Sustained-Release Imatinib Mesylate Tablet

Abstract

IntroductionImatinib mesylate is an antineoplastic agent which has high absorption in the upper part of the gastrointestinal tract (GIT). Conventional imatinib mesylate (Gleevec) tablets produce rapid and relatively high peak blood levels and requires frequent administration to keep the plasma drug level at an effective range. This might cause side effects, reduced effectiveness and poor therapeutic management. Therefore, floating sustained-release Imatinib tablets were developed to allow the tablets to be released in the upper part of the GIT and overcome the inadequacy of conventional tablets.MethodologyFloating sustained-release Imatinib mesylate tablets were prepared using the wet granulation method. Tablets were formulated using Hydroxypropyl Methylcellulose (HPMC K4M), with Sodium alginate (SA) and Carbomer 934P (CP) as release-retarding polymers, sodium bicarbonate (NaHCO3) as the effervescent agent and lactose as a filler. Floating behavior, in vitro drug release, and swelling index studies were conducted. Initial and total drug release duration was compared with a commercial tablet (Gleevec) in 0.1 N HCl (pH 1.2) at 37 ± 0.5°C for 24 hours. Tablets were then evaluated for various physical parameters, including weight variation, thickness, hardness, friability, and drug content. Consequently, 6 months of physical stability studies and in vitro gastro-retentive studies were conducted.Results and DiscussionStatistical data analysis revealed that tablets containing a composition of 14.67% w/w HPMC K4M, 10.67%, w/w Na alginate, 1.33%, w/w Carbomer 934P and 9.33%, w/w NaHCO3 produced the most favorable formulation to develop 24-hour sustained-release tablets with optimum floating behavior and satisfactory physicochemical characteristics. Furthermore, in vitro release study revealed that the formulated SR tablet had significantly lower Cmax and higher Tmax compared to the conventional tablet (Gleevec). Thus, formulated SR tablets preserved persistent concentration of plasma up to 24 hours.ConclusionIn conclusion, in order to suggest a better drug delivery system with constant favorable release, resulting in optimized absorption and less side effects, formulated CP-HPMC-SA based imatinib mesylate floating sustained-release tablets can be a promising candidate for cancer chemotherapy.

Ciprofloxacin HCl-loaded calcium carbonate nanoparticles: preparation, solid state characterization, and evaluation of antimicrobial effect against Staphylococcus aureus

“…Considering the RSQ of 0.99 and PE of 3.38%, the drug release data were best fitted to the Higuchi model. Higuchi's kinetic model can be used to describe the drug release from different kinds of modified release dosage forms (Kadivar et al 2015). This model explains the release of drugs from insoluble matrix as a square root of time-dependent process based on Fickian diffusion equation (Kalam et al 2007, Ofoefule andChukwu 2002).…”

Anticancer Properties of Halogenated Pyrrolo[3,2‐d]pyrimidines with Decreased Toxicity via N5 Substitution

“…Alkyl and oxyalkyl groups are common nitrogen substituents in pyrrolopyrimidines [17] , and sulfonyl groups are not uncommon in FDA approved anticancer drugs, often as salts formations, lending validity to the biological compatibility of these groups. [18] Introduction of a benzyloxymethyl moiety in 8 decreased the efficacy of the compound against all cell lines, and was not pursued further. N5 toluenesulfonyl substitution in compound 9 led to a four-fold increase in maximum tolerated dose compared to parent compound 7 , with comparable cell activity.…”

Gastro-Floating Tablets of Repaglinide: Preparation and in Vivo Evaluation

“…Plasma was separated by centrifugation of the blood at 5000 rpm in cooling centrifuge for 5 min to 10 min and stored frozen at −20°C until analysis [19].…”